Developmental reserch of the novel therapy for intractable pulmonary diseases such as pulmonary fibrosis
Project/Area Number |
23591167
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Respiratory organ internal medicine
|
Research Institution | Hyogo Medical University |
Principal Investigator |
|
Project Period (FY) |
2011 – 2013
|
Project Status |
Completed (Fiscal Year 2013)
|
Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2013: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2012: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2011: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
Keywords | バイオマーカー / サイトカイン / 酸化ストレス / 間質性肺炎 / 血管新生 / レチノイド / サリドマイド / 中皮腫 / 慢性閉塞性肺疾患 |
Research Abstract |
Malignant pleural mesothelioma (MPM) is an aggressive malignant tumor of mesothelial origin that shows a limited response to conventional chemotherapy and radiotherapy. Therefore, diagnosing MPM early is very important. We demonstrated that patients with MPM had significantly higher serum levels of some markers such as HMGB1, thioredoxin, angiopoietin-1 than the population who had been exposed to asbestos but had not developed MPM. The difference in overall survival between groups with serum HMGB1 and angiopoietin-1 levels that were lower and higher than assumed cut-off values was significant. Our data suggest that serum HMGB1, thioredoxin and angiopoietin-1 concentrations are useful clinical markers for MPM.
|
Report
(4 results)
Research Products
(33 results)
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
[Journal Article] Heme oxygenase-1 promoter polymorphism is associated with risk of malignant mesothelioma2012
Author(s)
Murakami A, Fujimori Y, Yoshikawa Y, Yamada S, Tamura K, Hirayama N, Terada T, Kuribayashi K, Tabata C, Fukuoka K, Tamaoki T, Nakano T.
-
Journal Title
Lung.
Volume: 190
Issue: 3
Pages: 333-7
DOI
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-